Your browser doesn't support javascript.
loading
Docosahexaenoic acid eliminates endoplasmic reticulum stress and inflammatory pathways in diabetic rat keratopathy.
Gezer, Arzu; Özkaraca, Mustafa; Üstündag, Hilal; Soydan, Menekse; Alkanoglu, Ömer; Bedir, Gürsel.
Afiliación
  • Gezer A; Vocational School of Health Services, Atatürk University, Erzurum, Turkiye; Pharmaceutical Research and Development, Graduate School of Natural and Applied Sciences, Atatürk University, Erzurum, Turkiye. Electronic address: arzu.gezer@atauni.edu.tr.
  • Özkaraca M; Faculty of Veterinary Medicine, Department of Pathology, Sivas Cumhuriyet University, Sivas, Turkiye.
  • Üstündag H; Department of Physiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkiye. Electronic address: hilal.ustundag@erzincan.edu.tr.
  • Soydan M; Institute of Natural Sciences, Sakarya University, Sakarya, Turkiye.
  • Alkanoglu Ö; Atatürk University, Faculty of Veterinary Medicine, Department of Biochemistry, Erzurum, Turkiye.
  • Bedir G; School of Medicine, Department of Histology and Embryology, Ataturk University Erzurum, Turkiye.
Int Immunopharmacol ; 140: 112871, 2024 Oct 25.
Article en En | MEDLINE | ID: mdl-39111146
ABSTRACT
Diabetic keratopathy, characterized by corneal structural changes, is a common complication of diabetes mellitus (DM). Docosahexaenoic acid (DHA), an omega-3 fatty acid, has shown potential therapeutic benefits in various diabetic complications. This study aimed to investigate the protective effect of DHA on corneal tissue in streptozotocin (STZ)-induced type 2 DM in rats. Forty male Sprague-Dawley rats were randomly assigned to four groups (n = 10 per group) Control, DHA, DM, and DM + DHA. The DHA group received DHA by oral gavage at a dose of 100 mg/kg daily for 10 days. In the DM group, diabetes was induced by a single intraperitoneal injection of STZ at 50 mg/kg. Confirmation of diabetes induction was based on monitoring fasting blood glucose levels on the third day post-injection. The DM + DHA group underwent the same diabetes induction protocol with STZ and received DHA at 100 mg/kg daily via oral gavage for 10 consecutive days. Corneal tissue samples were collected at the end of the study period for histopathological, immunohistochemical, qRT-PCR, and ELISA analyses. Histopathological analysis showed significant edema, angiogenesis, and degeneration in the DM group compared to the control (p < 0.001). DHA treatment significantly mitigated these changes, approaching control levels (p < 0.01). Immunohistochemistry showed increased VEGFR2 and iNOS expression in the DM group, which was significantly reduced in the DM + DHA group (p < 0.01). qRT-PCR results indicated a significant decrease in Bcl-2 expression (p < 0.001) and an increase in ATF-6, IRE1, NF-κB, TNF-α, IL-1ß, NLRP3, Bax, and Caspase-3 expressions in the DM group (p < 0.001). ELISA analyses revealed significantly elevated levels of inflammatory markers NF-κB, TNF-α, IL-1ß, and IL-6 in the DM group compared to the control (p < 0.001). DHA treatment significantly upregulated Bcl-2 and downregulated apoptotic and inflammatory markers (p < 0.01). DHA demonstrated significant protective effects against STZ-induced corneal damage in diabetic rats by modulating apoptotic and inflammatory pathways. These findings suggest that DHA may be a promising therapeutic agent for preventing diabetic keratopathy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácidos Docosahexaenoicos / Ratas Sprague-Dawley / Diabetes Mellitus Experimental / Estrés del Retículo Endoplásmico Límite: Animals Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácidos Docosahexaenoicos / Ratas Sprague-Dawley / Diabetes Mellitus Experimental / Estrés del Retículo Endoplásmico Límite: Animals Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos